Osivax

Osivax is a France-based international organization registered as a for-profit entity that specializes in the development of broadly protective influenza vaccines and related immunological technologies. The company has established itself as a key strategic partner to the U.S. federal government in advancing pandemic preparedness and biodefense capabilities through innovative vaccine platform technologies. Osivax leverages its proprietary OligoDOM platform technology to develop next-generation vaccine candidates capable of providing broad-spectrum protection against multiple influenza strains, addressing a critical gap in current seasonal and pandemic vaccine effectiveness.

Through federal contract awards, Osivax has secured substantial support from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response (ASPR) for clinical development and regulatory advancement activities. The company was awarded a $98.6 million definitive contract on July 25, 2025, to conduct clinical proof-of-concept studies for OVX836, its single-shot broadly protective influenza A vaccine designed to provide immediate protection against emerging pandemic strains; this contract represents a cost-sharing arrangement with a completion date of July 24, 2028 and originated from a Broad Agency Announcement issued by the Biomedical Advanced Research and Development Authority (BARDA). Additionally, Osivax received a $743,969.31 firm fixed-price contract awarded on September 30, 2025, to prepare a comprehensive Investigational New Drug (IND) package for OVX836+SQ adjuvant, with completion scheduled for March 31, 2027. Both contracts are classified as definitive contracts with no set-aside designations and reflect BARDA's commitment to developing pandemic preparedness capabilities through strategic investments in vaccine platform technologies advancing toward FDA approval or licensure.

Osivax has also received federal grant support through the National Institute of Allergy and Infectious Diseases (NIAID), which awarded the company a project grant on September 26, 2023, to conduct research on broad spectrum protection and immune responses induced by an NP-based universal influenza vaccine in heterologous nonhuman primate challenge models. This grant, which has an ultimate completion date of August 31, 2026, supports preclinical research demonstrating that Osivax's OVX836 vaccine candidate generates high, long-lasting, and dose-dependent humoral and T-cell responses with cross-protective efficacy against both homologous and heterologous influenza A and B strains. The research focuses on leveraging Osivax's proprietary OligoDOM platform technology to create heptameric antigens with improved immunogenicity by targeting nucleoprotein (NP), a highly conserved influenza antigen present across strains, thereby supporting the company's clinical development pathway and establishing the scientific foundation for its broader pandemic preparedness initiatives.